Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response

Show full item record



Permalink

http://hdl.handle.net/10138/252447

Citation

SUCCESS Study Investigators & Färkkilä , M 2010 , ' Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response ' , Hepatology , vol. 52 , no. 4 , pp. 1201-1207 . https://doi.org/10.1002/hep.23816

Title: Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
Author: SUCCESS Study Investigators; Färkkilä, Martti
Other contributor: University of Helsinki, Department of Medicine

Date: 2010-10
Language: eng
Number of pages: 7
Belongs to series: Hepatology
ISSN: 0270-9139
DOI: https://doi.org/10.1002/hep.23816
URI: http://hdl.handle.net/10138/252447
Abstract: The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RI3V) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-nave patients from 133 centers were treated with PEG-IFN alfa-26 (1.5 mu g/kg/week) plus RBV (800-1,400 mg/day). Patients with detectable hepatii is C virus (HCV) RNA and a >= 2-logio drop in IICV RNA levels at week 12 (slow responders) were randomized 1:1 to receive 48 weeks (n = 86) or 72 weeks (n = 73) of treatment. Sustained virologic response (SVR) rates were 43% in slow responders treated for 48 weeks and 48% in slow responders treated for 72 weeks (P = 0.644). Relapse rates were similar in slow responders treated for 48 or 72 weeks (47% versus 33%, P = 0.169). The safety profile was similar in both treatment arms; serious adverse events leading to discontinuation of treatment were observed in 3.5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a
Subject: PLUS RIBAVIRIN
TREATMENT DURATION
COMBINATION THERAPY
INFECTION
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Buti_et_al_2010_Hepatology.pdf 196.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record